Investment
Features
FeesSafety
Academy
More
Pluang+

Compare JPMorgan Ultra Short Income ETF (JPST) vs Stryker Corporation (SYK) Price & Performance

JPMorgan Ultra Short Income ETFTrade
Stryker CorporationTrade

Price performance (Past 24H)

Key statistics

JPMorgan Ultra Short Income ETF vs Stryker Corporation — how do they compare? JPMorgan Ultra Short Income ETF trades at $50.49, while Stryker Corporation trades at $316.25 (market cap $122.35B). The key difference: Stryker Corporation pays a 1% dividend while JPMorgan Ultra Short Income ETF pays none. Which is the better fit depends on your goals.

JPSTSYK
Sector
Leveraged / InverseTechnology
52-Week High
$50.78$403.53
52-Week Low
$50.40$282.58
Market Cap
$122.35B
Enterprise Value
$134.10B
Dividend Yield
1%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

JPMorgan Ultra Short Income ETF

JPST trades at $50.49, showing minimal daily movement with a slight decline of $0.01 (-0.02%). The technical outlook is bearish based on moving averages, while oscillators signal neutrality. Recent news highlights institutional interest, with Greenwood Gearhart LLC increasing its holdings by 9.6% as of July 2026. The ETF focuses on ultra-short income, offering a cash alternative with low duration risk, as noted in Seeking Alpha analysis from April 2026.

The outlook for JPST remains stable, appealing to risk-averse investors seeking capital preservation and modest income through dividends. Key risks include interest rate sensitivity and macroeconomic shifts affecting short-term bonds. Institutional accumulation supports confidence, but the bearish technical signal warrants caution for short-term traders.

Stryker Corporation

Stryker (SYK) trades at $319.14, down 0.23% on the day, with a bearish technical signal despite strong fundamentals. The company reported $25.12B revenue and $3.25B net income for 2025, maintaining robust profitability with 63.83% gross margins and 13.21% net margins. Recent Q1 2026 earnings missed expectations due to a cybersecurity disruption, but management maintained full-year guidance. Analyst consensus remains strongly bullish with a $388.44 price target and 74% buy ratings.

The stock presents a compelling opportunity for long-term investors given its strong fundamentals and innovation pipeline, though near-term technical weakness and competitive pressures warrant caution. Upside potential exists from continued Mako robotics adoption and market share gains, while risks include cybersecurity vulnerabilities and integration challenges from acquisitions.

Returns comparison

Trailing returns across standard periods

About JPMorgan Ultra Short Income ETF

JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.

Read more on JPST

About Stryker Corporation

Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.

Read more on SYK